151533-32-3

Upstream product

• 2008-75-5 N-chloroethylpiperidine hydrochloride 
• 130064-21-0 1-(2-hydroxy-4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)ethanone 
• 123-08-0 4-hydroxy-benzaldehyde 
• 26815-04-3 4-(2-(piperidin-1-yl)ethoxy)benzaldehyde 
• 110-89-4 piperidine 
• 110-87-2 3,4-dihydro-2H-pyran 
• 156-38-7 4-hydroxyphenylacetate 
• 108-46-3 recorcinol 
• 17720-60-4 2,4,4'-trihydroxy deoxybenzoin 

Downstream Products

• 361391-01-7 4,7-dihydroxy-3-(4-hydroxyphenyl)-2-[4-(2-piperidin-1-ylethoxy)-phenyl]-4-(trifluoromethyl)-2,3-dihydro-4H-1-benzopyran 
• 151533-33-4 4-hydroxy-4-methyl-2-(4'-[2''-piperidino]ethoxy)phenyl-3-(4'''-tetrahydropyranyloxy)phenyl-7-tetrahydropyranyloxychromane 
• 151533-34-5 2-[4-[2-(1-piperidino)ethoxy]phenyl]-3-(4-hydroxyphenyl)-4-methyl-7-hydroxy-2H-1-benzopyran 
• 182167-04-0 EM-800 
• 182167-04-0 EM-776 
• 182167-02-8 Acolbifene 
• 182167-58-4 EM-651 

Relevant academic research and scientific papers

TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS

Novel methods for reduction or elimination of the incidence of hot flushes, vasomotor symptoms, and night sweats while decreasing the risk of acquiring breast, uterine or endometrial cancer and furthermore having beneficial effect by inhibiting the develo

TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total andro

4-fluoroalkyl-2h-benzopyrans anti-estogenic activity

This invention describes the new 4-fluoroalkyl-2H-benzopyrans of general formula I, in which Z is a straight-chain or branched-chain alkyl group with up to 5 carbon atoms that is fluorinated in at least one place, preferably a trifluoromethyl group, and R1, R2, X, Y and n have the meanings that are indicated in the description. The new compounds have at their disposal strong antiestrogenic action. In addition, they can have at their disposal estrogenic action that occurs in a tissue-selective manner. They can be used for the production of pharmaceutical agents, especially for the treatment of estrogen-dependent diseases and tumors and pharmaceutical agents for hormone replacement therapy (HRT) as well as for the prevention and treatment of osteoporosis.

An efficient process for the synthesis of trans-2,3-disubstituted-2,3- dihydro-4H-1-benzopyran-4-ones (Chroman-4-ones)

The piperidine catalyzed Knoevenagel condensation of 2'-aryl/alkyl-2- hydroxyacetophenones 7 and aryl/alkylaldehydes 8 in refluxing isopropyl alcohol with azeotropic removal of water affords, in high yield, equilibrium mixtures of E- and Z-chalcones 9 and